Navigation Links
New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions
Date:11/11/2010

dabigatran exposure and should generally be avoided. P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin, do not require dose adjustments. These results should not be extrapolated to other P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events. PRADAXA 150 mg resulted in a higher rate of major gastrointestinal (GI) bleeds and any GI bleeds compared to warfarin. In patients greater than or equal to 75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions.  These were commonly dyspepsia (including abdominal pain, upper abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, gastritis, and GI ulcer).  Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.  

For full PRADAXA prescribing information, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 188
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DUBLIN , Sept. 19, 2014 Research ... "Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) ... For the purposes of this report, the human ... The human microbiome market is expected to be ... grow at a CAGR of 22.3% within the forecast period ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/20/2014)... September 20, 2014 iFitDress.com, the popular ... for women, has recently unveiled its new collection of ... sale for special offer on these new outfits; it ... season. All customers can now buy cheap cocktail ... company’s sales representative says, “We have extensive experience in ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The excitement is building ... Mount Airy, North Carolina. This year the Surry Arts Council ... people from around the country who are still fans of the ... is a sitcom that aired on CBS from 1960 through 1968. ... show in American television history. Mount Airy, North Carolina is ...
(Date:9/20/2014)... PITTSBURGH, PA (PRWEB) September 20, 2014 "As ... left in their tanks," said an inventor from Tamaqua, Pa. ... are mounted on the backs of their chairs. My invention ... She developed the Kam Oxygen Sensor to make it easier ... ensures that the user knows when the tank is low. ...
(Date:9/20/2014)... Los Angeles, CA (PRWEB) September 20, 2014 ... power score of 3.1 out of 5, indicating a ... research firm IBISWorld, this score reflects current and future ... negotiate from historically high prices. Other factors that negatively ... volatility in demand for construction and the moderate switching ...
(Date:9/20/2014)... QueenBeeTickets.com is ready to offer discount Ariana Grande ... visit many cities in North America next year from ... , Click Here to view the inventory ... The star’s fans are not going to want to ... in a live performance. Ariana Grande concert tickets are ...
Breaking Medicine News(10 mins):Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2
... interaction with cyclosporine could lead to fatal complications ... People taking the immunosuppressant cyclosporine should avoid consuming ... and possibly lead to deadly consequences, new research ... rats taking cyclosporine -- commonly used to help ...
... 25 NeuroVasx, Inc., a medical device company that ... stroke, announced today that it has received CE Mark ... is a minimally invasive device for the embolization of ... of an artery in the brain. If ruptured, aneurysms ...
... to Assist Processing Plants.SHREVEPORT, La., March 25 Since ... proven to be effective on the poultry processing line ... Salmonella, E. coli , and Listeria . ... help control Campylobacter by pre-screening birds for their current ...
... The 2008 Frost & Sullivan European ... is presented to Ferring Pharmaceuticals. The award ... providing no-needle injection for human growth hormone ... and ZOMAJET VISION X, innovative no-needle delivery ...
... March 25 /PRNewswire-Asia-FirstCall/ -- China Medical,Technologies, Inc. ... a leading China-based,medical device company that develops, ... announced that the Company received,quality testing certificate ... ,SPR System,) from one of the State ...
... March 25 Curemark, LLC, a drug research and ... announced today that the U.S. Food and Drug Administration ... application to initiate its pivotal Phase III clinical trial ... to begin Phase III clinical trials at multiple sites ...
Cached Medicine News:Health News:Licorice May Block Absorption of Organ Transplant Drug 2Health News:NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System 2Health News:SteriFx Inc. Provides 'Solutions' to Combat Campylobacter 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 3
Indications For Usage: , Oral Surgery. , Maxillofacial surgery. ...
The Cuffed Endoflex endotracheal tube had a murphy eye, high volume, low pressure cuff., ,Endoflex endotracheal tubes are individual packaged in sterilized pouches, 10 units per box, 10 boxes pe...
... Angel® is an in-line, battery-powered disposable, lightweight ... warming device, capable of intravenous application and ... be used to help prevent fluid-induced hypothermia. ... to achieve 38°C (100.4°F) 3°C at a ...
Using the patient's own blood pressure as the driving force, CAVR circulates cold blood through the Level 1 heat exchanger and returns it to the patient at body temperature for rapid core rewarming....
Medicine Products: